Blurbs

Analysts Are Bullish on Top Healthcare Stocks: Abbott Labs (ABT), CytomX Therapeutics (CTMX)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Abbott Labs (ABTResearch Report), CytomX Therapeutics (CTMXResearch Report) and Denali Therapeutics (DNLIResearch Report) with bullish sentiments.

Abbott Labs (ABT)

J.P. Morgan analyst Robbie Marcus maintained a Buy rating on Abbott Labs on July 12 and set a price target of $125.00. The company’s shares closed last Wednesday at $105.74, close to its 52-week low of $101.24.

According to TipRanks.com, Marcus is a 4-star analyst with an average return of 6.9% and a 47.1% success rate. Marcus covers the Healthcare sector, focusing on stocks such as Bausch + Lomb Corporation, Integra Lifesciences, and Baxter International.

Abbott Labs has an analyst consensus of Moderate Buy, with a price target consensus of $131.00, representing a 23.2% upside. In a report released yesterday, Cowen & Co. also maintained a Buy rating on the stock with a $130.00 price target.

See today’s best-performing stocks on TipRanks >>

CytomX Therapeutics (CTMX)

BMO Capital analyst Etzer Darout maintained a Buy rating on CytomX Therapeutics today and set a price target of $3.00. The company’s shares closed last Wednesday at $1.30, close to its 52-week low of $1.19.

According to TipRanks.com, Darout is a 5-star analyst with an average return of 35.5% and a 51.8% success rate. Darout covers the Healthcare sector, focusing on stocks such as Arvinas Holding Company, Y-Mabs Therapeutics, and Fate Therapeutics.

CytomX Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $4.00, representing a 217.5% upside. In a report issued on July 6, BTIG also assigned a Buy rating to the stock with a $8.00 price target.

Denali Therapeutics (DNLI)

In a report released yesterday, Jessica Fye from J.P. Morgan maintained a Buy rating on Denali Therapeutics, with a price target of $67.00. The company’s shares closed last Wednesday at $34.33.

According to TipRanks.com, Fye is a 4-star analyst with an average return of 9.0% and a 52.9% success rate. Fye covers the Healthcare sector, focusing on stocks such as Crinetics Pharmaceuticals, Intra-Cellular Therapies, and Emergent Biosolutions.

Currently, the analyst consensus on Denali Therapeutics is a Strong Buy with an average price target of $64.75.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on ABT:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More
Videos
Videos

Latest News Feed